Welcome to NLS Pharmaceutics

We are seeking to design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are seeking to create new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.

Press Room

Interview with Alex Zwyer, CEO of NLS Pharmaceutics Ltd. (NLS) at The London Stock Exchange Studios. You can see more info of NLS Pharmaceutics on the media in our Press Room section

Latest News

  • Mar 2, 2020
    NLS Pharmaceutics Ltd. (NLS) Files Registration Statement for a Proposed Initial Public Offering
  • Jan 13, 2020
    Adare Pharmaceuticals and NLS Pharmaceutics collaborate to develop mazindol controlled release (CR) for the treatment of ADHD and narcolepsy
  • Sep 30, 2019
    NLS Pharmaceutics Ltd. Announces Notice of Allowance of a new U.S. Patent Covering Attention Deficit Hyperactivity Disorder strengthening the scope of NLS’ Patent Portfolio.
  • Aug 13, 2019
    NLS Pharmaceutics Ltd. (NLS) Announces a Reexamination Certificate by the USPTO Further Strengthening their ADHD Use Patent Validity
Contact us

NLS Pharmaceutics is very interested in hearing from you. Please find general contact information below.

Alter Postplatz 2
CH-6370 Stans NW

T: +41 41 618 80 00
F: +41 41 618 80 09

Your Name (required)

Your Email (required)


Your Message